FDA Grants EUA for InflaRx’s Gohibic (vilobelimab) to Treat Critically Ill COVID-19 Patients
InflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read more